Edition:
United States

Opiant Pharmaceuticals Inc (OPNT.OQ)

OPNT.OQ on NASDAQ Stock Exchange Capital Market

22.44USD
23 Feb 2018
Change (% chg)

$-0.19 (-0.84%)
Prev Close
$22.63
Open
$23.70
Day's High
$23.70
Day's Low
$22.20
Volume
7,594
Avg. Vol
12,641
52-wk High
$51.90
52-wk Low
$17.01

Latest Key Developments (Source: Significant Developments)

Opiant Pharma Announces Positive Data From A Phase I Clinical Study Of OPNT003
Monday, 12 Feb 2018 08:00am EST 

Feb 12 (Reuters) - Opiant Pharmaceuticals Inc ::OPIANT PHARMACEUTICALS INC - ANNOUNCES POSITIVE DATA FROM A PHASE I CLINICAL STUDY OF ITS PRODUCT CANDIDATE OPNT003.OPIANT PHARMACEUTICALS INC - ANTICIPATES TO SUBMIT A NEW DRUG APPLICATION FOR DRUG AND INTRANASAL DELIVERY DEVICE COMBINATION IN 2020.OPIANT PHARMACEUTICALS INC - ANTICIPATE SUBMITTING AN NDA FOR OPNT003 IN 2020.OPIANT - HAS FULL COMMERCIAL RIGHTS TO OPNT003; SUBMITTED GRANT APPLICATION TO NATIONAL INSTITUTES OF HEALTH TO FUND DEVELOPMENT TO NDA READY STAGE.  Full Article

Opiant Pharmaceuticals To Record About $11.7 Million In Royalty
Thursday, 8 Feb 2018 08:00am EST 

Feb 8 (Reuters) - Opiant Pharmaceuticals Inc ::OPIANT PHARMACEUTICALS TO RECORD APPROXIMATELY $11.7 MILLION IN ROYALTY AND MILESTONE PAYMENTS RELATED TO 2017 SALES OF NARCAN® NASAL SPRAY FOR OPIOID OVERDOSE.OPIANT PHARMACEUTICALS - ‍WILL RECORD TOTAL OF ABOUT $11.7 MILLION ROYALTY, MILESTONE PAYMENTS FOR 5-MONTH TRANSITION PERIOD ENDED DECEMBER 31, 2017​.  Full Article

Opiant Pharma Reports Financial Developments Related To Narcan Nasal Spray For Opioid Overdose
Wednesday, 20 Dec 2017 08:00am EST 

Dec 20 (Reuters) - Opiant Pharmaceuticals Inc ::OPIANT PHARMACEUTICALS ANNOUNCES SIGNIFICANT FINANCIAL DEVELOPMENTS RELATED TO NARCAN® NASAL SPRAY FOR OPIOID OVERDOSE.OPIANT PHARMACEUTICALS -EXPECTS ,BEGINNING Q1 2018, CO WILL RECEIVE 90% ROYALTY, MILESTONE PAYMENTS RELATED TO NARCAN SALES DIRECTLY FROM ADAPT PHARMA​.OPIANT PHARMACEUTICALS - ROYALTY & MILESTONE PAYMENTS DUE TO SWK HOLDINGS WILL NOW BE REDUCED TO 10%.  Full Article

Opiant Pharmaceuticals, Inc. Reports Qtrly ‍net Loss Per Common Share $2.77​
Monday, 4 Dec 2017 04:05pm EST 

Dec 4 (Reuters) - Opiant Pharmaceuticals Inc ::OPIANT PHARMACEUTICALS, INC. REPORTS FISCAL FIRST QUARTER 2018 FINANCIAL RESULTS.OPIANT PHARMACEUTICALS INC - QTRLY ‍NET LOSS PER COMMON SHARE $2.77​.  Full Article

Opiant pharmaceuticals says ‍may offer & sell its shares through Cantor Fitzgerald
Thursday, 19 Oct 2017 07:12am EDT 

Oct 19 (Reuters) - Opiant Pharmaceuticals Inc :Opiant Pharmaceuticals says ‍may offer & sell through Cantor Fitzgerald its shares having aggregate offering price of up to $25 million - SEC filing​.  Full Article

Opiant Pharmaceuticals files for mixed shelf of upto $150 mln
Monday, 16 Oct 2017 03:25pm EDT 

Oct 16 (Reuters) - Opiant Pharmaceuticals Inc :Opiant Pharmaceuticals Inc files for mixed shelf of upto $150 million - sec filing ‍​.  Full Article

Opiant Pharmaceuticals reports Q4 loss per share $0.17‍​
Friday, 13 Oct 2017 07:00am EDT 

Oct 13 (Reuters) - Opiant Pharmaceuticals Inc :Opiant Pharmaceuticals Inc reports fiscal fourth quarter and full year 2017 financial results and provides corporate update.Q4 revenue $3.75 million versus $300,000.‍Opiant Pharmaceuticals Inc - appointed David O'Toole as chief financial officer​.Opiant Pharmaceuticals Inc - qtrly loss per share $0.17‍​.  Full Article

Opiant Pharma, Titan Pharmac to explore new treatments for opioid abuse
Monday, 2 Oct 2017 07:00am EDT 

Oct 2 (Reuters) - Opiant Pharmaceuticals Inc :Opiant Pharmaceuticals and Titan Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment.Opiant Pharma - co, Titan will conduct feasibility assessment of a subcutaneous implant using titan's proprietary proneura sustained release technology.  Full Article

Opiant Pharmaceuticals Inc provides an update on Narcan nasal spray
Friday, 15 Sep 2017 07:00am EDT 

Sept 15 (Reuters) - Opiant Pharmaceuticals Inc :Opiant Pharmaceuticals Inc provides an update on Narcan nasal spray.Opiant Pharmaceuticals Inc - ‍Adapt has maintained price of Narcan nasal spray, including a discounted public interest price of $75 per two-dose pack​.Opiant Pharmaceuticals Inc says ‍in over 40 states, Narcan nasal spray can now be purchased from pharmacies without a prescription​.Opiant Pharmaceuticals - ‍Narcan surpasses $25 million of net sales for H1 calendar 2017, triggering SWK Funding Llc's obligation to pay co additional $3.75 million​.  Full Article

Opiant Pharmaceuticals says co and Torreya Partners entered into a supplemental engagement letter
Thursday, 14 Sep 2017 05:14pm EDT 

Sept 15 (Reuters) - Opiant Pharmaceuticals Inc :Opiant Pharmaceuticals Inc - ‍on September 8, co and Torreya Partners entered into a supplemental engagement letter effective September 7​.Opiant Pharmaceuticals Inc - ‍supplemental agreement modifies and supplements engagement letter dated December 18, 2014.​.  Full Article

BRIEF-Opiant Pharma Announces Positive Data From A Phase I Clinical Study Of OPNT003

* OPIANT PHARMACEUTICALS INC - ANNOUNCES POSITIVE DATA FROM A PHASE I CLINICAL STUDY OF ITS PRODUCT CANDIDATE OPNT003